Results 111 to 120 of about 58,665 (272)

Dopamine agonists and risk of lung cancer in patients with restless legs syndrome. [PDF]

Pharmacoepidemiol Drug Saf, 2023
Hernandez-Con P, Shults J, Willis AW, Yang YX.   +3 more
europepmc   +1 more source

Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines

, 1988
Juan C. Jaén, Lawrence D. Wise, Thomas G. Heffner, Thomas A. Pugsley, Leonard T. Meltzer   +4 more
openalex   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment

, 2021
Muzaffar Ali, Lubna Mirza
openalex   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Metabolic effects of prolactin and the role of dopamine agonists: A review. [PDF]

Front Endocrinol (Lausanne), 2022
Kirsch P, Kunadia J, Shah S, Agrawal N.
europepmc   +1 more source

Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D3 receptor-selective full agonist ligand

, 2012
Alia H. Clark, John D. McCorvy, Jason M. Conley, Whitney K. Williams, B. Markondaiah, Val J. Watts, David E. Nichols   +6 more
openalex   +2 more sources

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, EarlyView.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease

, 2016
E. Suárez Castro, Diego Santos‐García, Teresa de Deus Fonticoba, Irene Expósito Ruíz, Cintia Tuñas Gesto, Mercedes Macías Arribí   +5 more
openalex   +1 more source

Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment [PDF]

, 2010
Karen D. Ersche, Jonathan P. Roiser, Mark Lucas, Enrico Domenici, Trevor W. Robbins, Edward T. Bullmore   +5 more
openalex   +1 more source